BRAF and neoplasm: Recent approvals of tumor-agnostic therapies encompass drugs targeting mutations/rearrangements in genes such as isocitrate dehydrogenase 1 (IDH1) [111], neurotrophic tropomyosin-receptor kinase (NTRK) [112], the V600E mutation of the BRAF gene (BRAFV600E) [113], and tumors with high tumor mutational burden, high microsatellite instability, and gene mismatch repair-deficiency (TMB-H/MSI-H/dMMR) [114].